Dr Reddy's Labs (DRREDDY)

FairStock Score: 63/100 — STEADY

Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• ROCE of 22.69% and ROE of 16.60% with debt/equity of 0.16 reflect strong capital efficiency and low leverage.
• Altman Z-Score of 3.30 and Piotroski F-Score of 7/9 suggest the balance sheet is financially stable.
• Five-year revenue CAGR of 11.38% shows a proven growth record; latest quarter sales of ₹8,753 crore and net profit of ₹1,190 crore remain healthy.
• FairStock Score of 69/100 (STEADY) reinforces that this is a consistent, non-cyclical performer.

Concerns

• Negative free cash flow of ₹1,142 crore despite reported profit raises earnings quality questions.
• Profit growth of -4.63% and sales growth slowing to 6.38% from the 5-year CAGR of 11.38% point to deceleration.
• Valuation is demanding: P/E of 19.28, EV/EBITDA of 32.82, PEG of 18.65, and a -65.45% margin of safety versus the Graham Number of ₹777.45.
• Promoter holding of 26.64% is modest; alignment with minority shareholders is weaker than I prefer.

AI Analysis

Let me evaluate Dr Reddy's the way I would any business: by earnings power, balance sheet, and price. The quality signals are encouraging. Return on equity is 16.60%, return on capital employed is 22.69%, and debt-to-equity is just 0.16. That is a company generating solid returns without loading up on borrowed money. Five-year revenue CAGR of 11.38% also tells me this has been a compounder. But latest annual profit growth is -4.63%, sales growth has slowed to 6.38%, and free cash flow is negative at ₹1,142 crore. As Graham taught, cash is the ultimate reality; profits without cash can be a warning. The balance sheet is not in distress. Altman Z-Score of 3.30 and Piotroski F-Score of 7/9 point to stability. The latest quarter, with sales of ₹8,753 crore and net profit of ₹1,190 crore, shows the engine still works. My hesitation is price. At ₹1,331, the P/E is 19.28, P/B is 3.31, EV/EBITDA is 32.82, and PEG is 18.65. The Graham Number is only ₹777.45, and the margin of safety is -65.45%. That is not a bargain; it is a high-quality business selling at a premium. Dividend yield of 0.62% offers little while I wait. Promoter holding is 26.64%, which is modest. I prefer owner-operators with more skin in the game. Dr Reddy's may be a fine stalwart in India's pharma landscape, but a wonderful business at too high a price can still be a poor investment. I will keep it on my watchlist and wait for either a lower price or clear evidence that growth and cash conversion have accelerated.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer